.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Healthtrust
Dow
McKesson
Fish and Richardson
Accenture
Teva
Johnson and Johnson
Moodys
US Department of Justice

Generated: December 17, 2017

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Germany Patent: 196 16 486

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer IngelheimGLYXAMBIempagliflozin; linagliptinTABLET;ORAL206073-001Jan 30, 2015RXYesNo► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Boehringer IngelheimGLYXAMBIempagliflozin; linagliptinTABLET;ORAL206073-002Jan 30, 2015RXYesYes► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN
Boehringer IngelheimJENTADUETOlinagliptin; metformin hydrochlorideTABLET;ORAL201281-001Jan 30, 2012RXYesNo► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
Boehringer IngelheimJENTADUETOlinagliptin; metformin hydrochlorideTABLET;ORAL201281-002Jan 30, 2012RXYesNo► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
Boehringer IngelheimJENTADUETOlinagliptin; metformin hydrochlorideTABLET;ORAL201281-003Jan 30, 2012RXYesYes► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
Boehringer IngelheimJENTADUETO XRlinagliptin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208026-001May 27, 2016RXYesNo► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
Boehringer IngelheimJENTADUETO XRlinagliptin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208026-002May 27, 2016RXYesYes► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
Boehringer IngelheimTRADJENTAlinagliptinTABLET;ORAL201280-001May 2, 2011RXYesYes► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR
Boehringer IngelheimTRADJENTAlinagliptinTABLET;ORAL201280-001May 2, 2011RXYesYes► Subscribe► SubscribeMETHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE)
Merck Sharp DohmeJANUMETmetformin hydrochloride; sitagliptin phosphateTABLET;ORAL022044-001Mar 30, 2007RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist